CytoDyn Inc brings on Yahoo!, Shutterfly veteran law expert

CytoDyn Inc (OTCMKTS:CYDY) has added corporate law veteran Maura Fleming to its leadership team as vice president, general counsel and corporate secretary. 

Fleming joins the biotechnology company after serving as counsel for Holland & Hart LLP, where she provided legal expertise and contract management services to the food and beverage, technology, manufacturing and other industries.  

“We are excited to welcome Maura to the CytoDyn team,” CEO Nader Pourhassan said in a statement. “Her entrepreneurial spirit, broad legal background and experience in navigating the corporate life cycle strengthens our leadership team at this pivotal time. Maura will assist the CytoDyn team execute its goals as the Company continues to advance its targeted therapy, leronlimab, to address cancer, HIV and other autoimmune diseases.”

READ: CytoDyn’s impressive run continues for leronlimab in metastatic triple-negative breast cancer and metastatic breast cancer

Fleming has also held the role of senior corporate counsel at Shutterfly, was the director of legal services at Aerohive Networks Inc and began her career at Yahoo! Inc, where she spent seven years. 

All in all, she brings more than a decade of corporate transactional law experience.

“I am honored to join CytoDyn and look forward to leveraging my strategic and legal insight to advise the Company during this unprecedented period of extensive growth and evolution. I am eager to start working alongside the leadership team and support the continuing evolution of its corporate governance, transactions and other legal challenges.”

CytoDyn, based in Vancouver, Washington, is developing the drug candidate leronlimab to battle multiple diseases. The company has filed an Investigational New Drug (IND) application and a Phase 2 clinical trial protocol with the US Food and Drug Administration (FDA) for leronlimab to treat patients with NASH.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Story by ProactiveInvestors